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We present a case report of a 35-year-old woman who had splenic infarction. She had persistent high fever, systemic joint pain,
and abnormal liver function. She was diagnosed with cytomegalovirus and human parvovirus B19 concomitant infection. Her
coagulopathy test revealed no abnormal results. She was treated with intravenous ganciclovir for 13 days; consequently, her
splenic infarction improved after 7 weeks. As per our knowledge, this is the first case of cytomegalovirus and parvovirus B19
coinfection complicated by splenic infarction. Cytomegalovirus and parvovirus B19 may induce a hypercoagulation state during
the acute phase.
1. Introduction
Infectious mononucleosis is commonly caused by
Epstein–Barr virus (EBV) infection, which is characterized
by pharyngitis, lymphadenopathy, atypical lymphocytosis,
and hepatosplenomegaly. Although cytomegalovirus (CMV)
infection is commonly asymptomatic, approximately 10% of
adults who are initially infected with CMV present with
infectious mononucleosis. CMV is the second most com-
mon cause of infectious mononucleosis [1]. Recently, the
rate of young adults who are infected with CMV has de-
creased; in fact, the serological prevalence rate of CMV
among pregnant women is approximately 69% in Japan [2].
Human parvovirus B19 is well known for causing erythema
infectiosum in children. Nontypical symptoms of poly-
arthropathy, erythema, and red cell aplasia have been ob-
served in adult infections, and in rare cases, it is the cause of
infectious mononucleosis. Although infectious mono-
nucleosis is usually a self-limiting disease and has a good
prognosis, several complications, including hematological
complications, can occur. Splenic rupture is one of the most
serious complications of infectious mononucleosis and
occurs in only 0.1% of patients [3]. Splenic infarction rarely
occurs in infectious mononucleosis. As per our knowledge,
there has been no previous report of splenic infarction due to
CMV and parvovirus coinfection.
Herein, we report the case of a young woman with
infectious mononucleosis-like syndrome who developed
splenic infarction during the acute phase of CMV and
parvovirus B19 concomitant infection. After treatment with
ganciclovir, her splenic infarction improved.
2. Case Presentation
A 35-year-old woman was referred to our hospital after
having high fever and systemic joint pain for 10 days. She
was admitted to our hospital for further examination and
treatment. She had a past medical history of diabetes mel-
litus, herpes zoster, and lichen planus; her family history was
unremarkable. On admission, her body temperature was
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38.3°C, her blood pressure was 119/90mmHg, her pulse rate
was 110 beats/min, and the oxygen saturation in the room
air was 97%. Erythematous papule appeared on the anterior
chest and bilateral forearm. She had no pharyngitis,
lymphadenopathy, or abdominal pain. Her total white blood
cell count was 9,200/µL (neutrophils 87%, lymphocytes 7%,
and atypical lymphocytes 2%), CD4+ Tcell was 44.3%, CD8+
T cell was 34.5%, hemoglobin was 15.3 g/dL, and platelet
count was 123,000/µL. Her laboratory test results were as
follows (Table 1): C-reactive protein level, 6.83mg/dL; as-
partate transaminase, 96U/L; alanine transaminase, 130U/
L; alkaline phosphatase, 489U/L; c-glutamyl transpeptidase,
349U/L; lactate dehydrogenase, 315U/L; total bilirubin,
1.2mg/dL; HbA1c, 8.7%; immunoglobulin G, 1574mg/dL;
immunoglobulin A, 186mg/dL; immunoglobulin M,
144mg/dL. *e results of the serological tests for hepatitis B
and C were negative. *e result of renal function test was
normal. Urinalysis showed negative occult blood and uri-
nary protein. *e blood cultures showed no growth. Because
the patient continued to have high fever, we performed an
abdominal computed tomography (CT) scan, which
revealed splenomegaly and a geographic low attenuation
area in the dorsal and upper external side of the spleen
(Figures 1(a) and 1(b)); this finding was consistent with
splenic infarction.
We considered the splenic infarction to be in a hyper-
coagulable state. Her coagulopathy tests showed the fol-
lowing results: prothrombin time, 14.9 sec (normal,
10.6–14.9 sec); activated partial thromboplastin time,
33.9 sec (normal, 23.3–38.2 sec); d-dimer, 6.4 µg/mL; lupus
anticoagulant, 1.05 (normal values <1.2, with dilute Russell’s
viper venommethod); anticardiolipin antibody IgG, <8.0U/
mL; and anticardiolipin-β2-glycoprotein I complex anti-
body, <1.2U/mL. *ere were no abnormal coagulopathy
results.
Because of atypical lymphocytosis and elevated trans-
aminase, infectious mononucleosis was considered the cause
of her sustained fever. *e serological test for EBV antiviral
capsid antigen IgM was negative at 0.1 (normal level, <0.5),
antiviral capsid antigen IgG was positive at 7.5 (normal level,
<0.5), and antibody to EBV nuclear antigen was positive at
4.6 (normal level, <0.5). *ese results suggest past infection
for EBV. *e serological test for CMV IgM was positive at
4.60 (normal level, <0.8), CMV IgG was slightly positive at
2.5 (normal level, <2.0), and parvovirus B19 IgM was also
slightly positive at 0.99 (normal level, <0.8). *e CMV
antigen pp65 (antigenemia method of C10C11) was de-
tectable at a level of 33 positive cells per 150,000 cells and 25
positive cells per 150,000 cells, which confirmed her di-
agnosis of acute CMV infection. *e results of the human
immunodeficiency virus type 1 (HIV-1) antigen/antibody
and human T-cell leukemia virus type-1 (HTLV-1) antibody
were negative. Although the patient was originally treated
with conservative therapy, her fever persisted; therefore, she
was subsequently treated with intravenous ganciclovir. *e
day after beginning the treatment with ganciclovir, her fever,
joint pain, and erythematous papule improved (Figure 2).
After 13 days of ganciclovir therapy, the CMV antigen pp65
was decreased at a level of 1 positive cells per 150,000 cells
and she was discharged. Two weeks after the first serological
tests of the virus antibodies, a follow-up serological test was
performed. CMV IgM was positive at 4.80, CMV IgG was
elevated to 11.7, and parvovirus B19 IgM was elevated to
2.38. Acute parvovirus infection was confirmed by the in-
creasing level of parvovirus B19 IgM antibody. Seven weeks
after discharge, we performed an additional abdominal CT
scan. *e splenic infarction area was decreased without
atrophy, and splenomegaly was improved (Figures 1(c) and
1(d)).
3. Discussion
Splenic infarction is an uncommon disorder that occurs
when splenic artery branches become occluded, either by an
embolus or thrombus. *e causes of splenic infarction are
cardiogenic emboli such as atrial fibrillation, autoimmune
diseases such as antiphospholipid syndrome, hematological
diseases, and infection. Various infectious diseases, such as
varicella zoster virus, HIV, and malaria, were previously
reported to cause splenic infarction. *e hypercoagulable
state caused by these diseases can induce thromboembolic
complications.
Infectious mononucleosis is mainly caused by EBV. Other
viruses such as CMV, human herpes virus type 6, parvovirus
B19, and HIV-1 can be associated with infectious
mononucleosis-like syndrome with atypical lymphocytes [1].
*e most widely used diagnostic criterion of infectious
mononucleosis is Hoagland’s criterion. For patients presenting
with clinically suspected infectious mononucleosis and at least
a 50% lymphocytosis and 10% atypical lymphocytes, the di-
agnosis should be confirmed by the positive serologic test to
EBV. But these criteria are not high sensitivity [4]. Although
present case had high fever, splenomegaly, detected viral
antigen, and increased in titer of antibodies to CMV and
parvovirus B19, atypical lymphocytes were only 2%. We di-
agnosed this case as infectious mononucleosis-like syndrome
caused by CMV and parvovirus B19. *e incidence of splenic
infarction as a complication of infectious mononucleosis is
extremely rare. A 10-year retrospective case series revealed that
49 patients developed splenic infarction out of approximately
60,000 total patients [5]. Only 2 of those 49 patients were
diagnosed with infectious mononucleosis caused by EBV.
Another retrospective case series showed only 32 patients
with splenic infarction, corresponding to a frequency of
0.016% over 10 years of admissions [6]. Although 4 patients
were diagnosed with infection-associated splenic infarction
in that study, no patients were diagnosed with infectious
mononucleosis.
In previously reported cases of infectious mono-
nucleosis with splenic infarction, the most abnormal
coagulopathy result was the transient appearance of anti-
phospholipid antibodies during the acute phase of in-
fectious mononucleosis as a result of EBV [7–9]. In
addition, CMV infection was reported to induce throm-
boembolisms, such as portal vein thrombosis and splenic
infarction [10–12]. *e most reported mechanism was also
the transient appearance of antiphospholipid antibodies
[13]. Uthman and Gharavi showed that anticardiolipin
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antibodies and lupus anticoagulant were associated with
viral infections such as hepatitis C virus, EBV, CMV, and
parvovirus B19 [14]. *romboses associated with CMV
were primarily reported in immunocompromised patients,
such as acquired immunodeficiency syndrome patients and
transplant recipients. Human parvovirus B19 infection
induced several unusual clinical manifestations, such as
vasculitis, myocarditis, glomerulonephritis, immune
Table 1: Clinical data of this case.
Hematology Serology Biochemistry
White blood cell 9200/μL CRP 6.83mg/dL Total bilirubin 1.2mg/dL
Neutrophil 87% IgG 1574mg/dL AST 96U/L
Lymphocyte 7% IgA 186mg/dL ALT 130U/L
Atypical lymph 2% IgM 144mg/dL ALP 489U/L
Hemoglobin 15.3 g/dL C3 122.0mg/dL γ-GTP 349U/L
Platelet 123,000/μL C4 22.1mg/dL LDH 315U/L
CD4 44.3% CH50 66.5U/mL BUN 8.4mg/dL
CD8 34.5% Ferritin 459 ng/mL Cr 0.47mg/dL
CD3 77.9% sIL-2R 1129U/mL HbA1c 8.7%
CD19 9.6% EBV-VCA IgM 0.1 HBs-Ag <0.001 IU/mL
EBV-VCA IgG 7.5 HCV-Ab 0.1 COI
EBV-EBNA IgG 4.6 HTLV-1 Ab 0.1 COI
CMV IgM 4.6 HIV-1 Ag/Ab 0.2 COI
CMV IgG 2.5
Parvovirus B19-IgM 0.99
CRP: C-reactive protein, IgG: immunoglobulin G, IgA: immunoglobulin A, IgM: immunoglobulinM, sIL-2R: soluble IL-2 receptor, EBV: Epstein–Barr virus,
VCA: virus capsid antigen, EBNA: EBV nuclear antigen, CMV: cytomegalovirus, AST: aspartate transaminase, ALT: alanine transaminase, ALP: alkaline
phosphatase, c-GTP: c-glutamyl transpeptidase, LDH: lactate dehydrogenase, BUN: blood urea nitrogen, Cr: creatinine, HBs-Ag: hepatitis B surface antigen,




Figure 1: Abdominal computed tomography at admission. (a) Enlarged liver and spleen are shown. (b) A geographical low attenuation area
is observed on the dorsal side of the spleen, which suggests splenic infarction. *ese findings were improved after ganciclovir treatment. (c)
Enlarged liver and splenomegaly were improved. (d) *e geographic low attenuation area in the spleen was decreased.
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thrombocytopenia, and hemophagocytic syndrome.
Splenic infarction is an extremely rare complication of
parvovirus B19 infection. To our knowledge, four cases of
thromboembolism associated with parvovirus B19 in-
fection have been previously described [15–18]. Although
these occurrences resulted in transient antiphospholipid
antibodies, one case did not have elevated titers of anti-
phospholipid antibodies, and the mechanism of throm-
boembolism was unknown in that case [15].
In nearly all cases of splenic infarction during viral
infection, transient antiphospholipid antibodies have been
documented. Although this may be the pathophysiological
mechanism of splenic infarction, antiphospholipid anti-
bodies were not detected in the present case. Another theory
suggests that CMV infects endothelial cells and enhances the
expression of adhesion molecules and tissue factors on their
surfaces. *is action results in platelet adhesion and ag-
gregation on vessel walls. Activation of factor X, increasing
levels of von Willebrand factor, and factor VIII are other
theories of the mechanism behind CMV-induced throm-
bosis [19]. Viral infection in itself may change the antico-
agulant environment of the vascular endothelium to favor
coagulation. Khoretonenko et al. showed that mice infected
with CMV displayed an impaired arteriolar vasodilator
response and that CMV induced transient leukocyte and
platelet adhesion in postcapillary venules [20]. *ese results
indicated that CMV infection induced microvascular dys-
function. Because the present case was infected with CMV
and parvovirus B19 simultaneously, it was supposed that the
environment of the vascular endothelium displayed a greater
change in coagulation.
Antopolsky et al. showed that diabetes mellitus was
presented in 23% of the patients who developed splenic
infarction; therefore, diabetes mellitus is considered one of
the risk factors for thrombosis [5]. Although this case
presented poorly controlled diabetes mellitus, splenic in-
farction was improved by treatment with ganciclovir. It was
indicated that viral infections were the main cause of splenic
infarction in this case. However, poorly controlled diabetes
mellitus might affect the clinical course of present case.
Cytomegalovirus infection is often a self-limiting disease;
however, this case had continued high fever for about 3
weeks and even needed treatment of ganciclovir. Although
we did not measure severity biomarker such as cytokines and
galectin, the severe clinical course indicated that hyper-
cytokinemia might be developed and might affect
coagulopathy.
*e route of infection in this case was equivocal, because
she does not have any children of her own. But she lived in
complex housing where many families lived with children
and she had frequent contact with these children. Fur-
thermore, she suffered from poor-controlled diabetes mel-
litus that induced immunocompromised state. She might
infect CMV and parvovirus B19 in this community, and
poor controlled diabetes mellitus might affect infection
structure.
In conclusion, this is the first documented case of CMV
and human parvovirus B19 concomitant infection compli-
cated with splenic infarction in which antiphospholipid
antibodies were not detected. Physicians should be aware of
thromboembolisms during the acute phase of viral in-
fections, particularly in patients infected with more than one
virus.
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